Total Price: $0.00
Contact Information
Recombinant Human CD32b/FCGR2B Protein (His tag)
SKU: PDMH100113-100
Recombinant Human CD32b/FCGR2B Protein (His tag)
| SKU # | PDMH100113 |
| Expression Host | HEK293 Cells |
Description
| Synonyms | CD32, CDw32, FCG2, FCGR2B, Fc-Gamma RII-b, Fc-Gamma-RIIb, FcRII-b, IGFR2, IgG Fc Receptor II-b, Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b |
| Species | Human |
| Expression Host | HEK293 Cells |
| Sequence | Thr43-Pro217 |
| Accession | P31994 |
| Calculated Molecular Weight | 19.1 kDa |
| Observed Molecular Weight | 30 kDa |
| Tag | C-His |
| Bio-activity | Not validated for activity |
Properties
| Purity | > 95% as determined by reducing SDS-PAGE. |
| Endotoxin | Please contact us for more information. |
| Storage | Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months. |
| Shipping | This product is provided as lyophilized powder which is shipped with ice packs. |
| Formulation | Lyophilized from sterile PBS, pH 7.4. Normally 5%-8% trehalose, mannitol and 0.01% Tween 80 are added as protectants before lyophilization. Please refer to the specific buffer information in the printed manual. |
| Reconstitution | It is recommended that sterile water be added to the vial to prepare a stock solution of 0.5 mg/mL. Concentration is measured by UV-Vis. |
Background
FcγRIIB is a low affinity receptor that recognizes the Fc portion of IgG. The human CD32 group consists of FcγRIIA, FcγRIIB, and FcγRIIC proteins that share 94-99% sequence identity in their extracellular domains but differ substantially in their transmembrane and cytoplasmic domains. FcγRII protein is expressed on cells of both myeloid and lymphoid lineages as well as on cells of non-hematopoietic origin. FcγRIIB has an intrinsic cytoplasmic immunoreceptor tyrosine-based inhibitory motif (ITIM) and delivers an inhibitory signal upon ligand binding. Ligation of FcγRIIB on B cells down-regulates antibody production and in some circumstances may promote apoptosis. Co-ligation of FcγRIIB on dendritic cells inhibits maturation and blocks cell activation. FcγRIIB may also be a target for monoclonal antibody therapy for malignancies. FcγRIIB plays an important negative-regulating role through modulating the signals from activation receptors.